Amgen said results from an exploratory analysis of an ongoing phase II study showed that subjects treated with denosumab sub-Q, 60 mg twice yearly for up to 24 months , experienced enhanced bone mineral density, as well as in parameters of hip structural analysis, which estimates bone strength.
Denosumab is a fully human monoclonal antibody that targets RANK ligand, which is a primary mediator of the formation, function and survival of osteoclasts. RANK is receptor activator of Nuclear Factor kappa B, which we have talked about in an earlier post. Post NfKB activation, a diverse array of genes are expressed in osteoclasts.
AMGEN, Nasdaq:AMGN closed up $1.03, to $72.01 in heavy trading.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment